Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 7
Primary Industries
- Drugs
- Cancer
- Radiation
- Disease
- Therapeutic
- Specialty
- Pharmaceuticals
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 370599
License Grant
Licensee from Cayman Islands obtained an exclusive, sublicensable license under certain patents and know-how of Licensor to develop, manufacture, use, sell, import and commercialize Licensor’s proprietary SHP2 inhibitor, BBP-398 (formerly known as IACS-15509) in the licensed territory of Mainland China, Hong Kong, Macau, Taiwan, Thailand, Singapore, and South Korea, in the licensed field of diagnostic, prophylactic, palliative, and therapeutic uses or indications in humans.
License Property
SHP2 inhibitor (BBP-398) (formerly known as IACS-15509) is an orally available allosteric inhibitor of SHP2, a tyrosine phosphatase that plays a key role in the RTK-mediated MAPK signal transduction pathway.
Field of Use
Licensed field is for diagnostic, prophylactic, palliative, and therapeutic uses or indications in humans including for the potential treatment of MAPK-driven solid tumors.
MAPK (mitogen-activated protein kinase) pathway is a central axis driving aberrant proliferation in a broad spectrum of cancers.
IPSCIO Record ID: 372929
License Grant
Licensor granted to the Licensee of the Cayman Islands an exclusive license under certain patents and know-how of Licensor to develop and commercialize Licensor’s proprietary product NBTXR3 in the territory of Mainland China, Macau, Hong Kong, Thailand, Taiwan, South Korea and Singapore, in the licensed field of use of a product activated by radiotherapy in oncology. Licensee will participate in a global phase III registrational study in head and neck cancer for the licensed product and four additional registrational studies across indications and therapeutic combinations. We are obligated to use commercially reasonable efforts to enroll a certain percentage of study patients in the territory in such studies.
License Property
NBTXR3, a radiosensitizer designed to be injected directly into a malignant tumor prior to standard radiotherapy. When exposed to ionizing radiation, NBTXR3 has been shown to enhance the localized effect of radiotherapy. NBTXR3 is designed to enhance the effect of radiotherapy without resulting in additional side effects on surrounding healthy tissue. NBTXR3 may also prime the body’s immune response against cancer, and clinical activity has been observed across a number of different solid tumor types and in combination with immuno-oncology agents. Clinical proof of concept for NBTXR3 has been demonstrated in soft tissue sarcoma.
Field of Use
Field of Use is for radiotherapy treatment in oncology.
IPSCIO Record ID: 241600
License Grant
The Licensor grants to the Cayman Islands Licensee an exclusive royalty-bearing, non-sublicensable, non-transferable license under the Licensor Technology and interest in the Joint Combination Therapy Technology to Commercialize Licensed Products in the Field in the Territory.
License Property
Technology relates to he oral inhibitor enzyme is Ivosidenib for the treatment of hematologic and solid tumor indications. Ivosidenib is an investigational, first-in-class, oral, targeted inhibitor of the mutant isocitrate dehydrogenase-1 (IDH1) enzyme.
Ivosidenib is an investigational first-in-class, orally available, selective, potent inhibitor of the mutated IDH1 protein and is a highly targeted investigational medicine for the treatment of patients with cancers that harbor an IDH1 mutation. IDH1 is a metabolic enzyme that is mutated in a wide range of cancers, including acute myeloid leukemia, cholangiocarcinoma and glioma. Ivosidenib is currently under U.S. FDA priority review for IDH1m R/R AML patients with a PDUFA action date of August 21, 2018.
Field of Use
Licensee has expertise in the development of biopharmaceutical products and will be responsible for conducting the development and commercialization activities for ivosidenib in hematologic and solid tumor indications.
IPSCIO Record ID: 33130
License Grant
The Licensor of Hong Kong and Licensee of China agree to collaborate with respect to the Development of the Product in the Field with the goal of obtaining Regulatory Approval for Products in the Field in the Territory for Manufacturing and Commercialization. Lilly will have exclusive rights to Commercialize the Products in the Field in the Territory.
For the Exclusive License and Right to Sublicense, Licensor grants an exclusive license, including the right to grant sublicenses, under Licensor Patents, Know-How and Regulatory Approvals to Develop, use, import and Commercialize, but, for clarity, not to make or have made Products in the Field in the Territory.
License Property
Licensor is the owner of a molecule HMPL-013 and is developing it for the Chinese market as a pharmaceutical product useful in the treatment of cancer.
Product means any form or dosage of the HMPL-013 molecule or any analogues or derivatives of the HMPL-013 molecule that are claimed by those Licensor Patents that also claim HMPL-013, in each case that exist as of the Effective Date or are discovered or developed by Licensor during the Term of this Agreement.
HMPL-013, named Fruquintinib, patents and patent applications report compounds related to Fruquintinib and compositions comprising at least one compound, and methods for inhibiting KDR activity and treating angiogenesis–related disorders with such compounds/compositions.
Fruquintinib is a selective inhibitor of the Vascular Endothelial Growth Factor (VEGF) receptor tyrosine kinases.
Combination Products means any combination or Product and one or more additional active pharmaceutical ingredients, for example in a single delivery device such as a pre-filled pen, dual chamber needle or in a fixed dose combination.
Fruquintinib is a highly selective and potent oral inhibitor of the vascular endothelial growth factor receptor, or VEGFR, and consequently we believe it has the potential to be a global best-in-class VEGFR inhibitor for many types of solid tumors. Based on pre-clinical and clinical data to date, fruquintinibs kinase selectivity has been shown to reduce off-target toxicity. This allows for drug exposure that is able to fully inhibit VEGFR, a protein ligand which contributes to the growth of tumors, and use in potential combinations with other targeted therapies and chemotherapy in earlier lines of treatment with larger patient populations.
Field of Use
Fruquintinib (HMPL-013), is a targeted oncology therapy for the potential treatment of various types of solid tumors.
The Field means all uses. Initial Indications mean 3rd line colorectal cancer, 3rd line non-small cell lung cancer and 2nd line advanced gastric cancer. Each of the Initial Indications shall be an Initial Indication.
IPSCIO Record ID: 319042
License Grant
Licensor and Hong Kong Licensee agreed to collaborate for the development and commercialization of uproleselan and GMI-1687 in Mainland China, Hong Kong, Macau and Taiwan, also known as Greater China and to advance the preclinical and clinical development of GMI-1687.
License Property
GMI-1687 is a potential life-cycle extension to uproleselan that has been designed as an innovative antagonist of E-selectin that could be suitable for subcutaneous administration.
Uproleselan is a glycomimetic drug candidate and a specific E-selectin inhibitor that is being developed to be used in combination with chemotherapy to treat patients with acute myeloid leukemia, or AML, a life-threatening hematologic cancer, and potentially other hematologic cancers.
E-selectin plays a critical role in binding cancer cells within vascular niches in the bone marrow, which prevents the cells from entering the circulation where they can be more readily killed by chemotherapy. Glycomimetics are molecules that mimic the structure of carbohydrates involved in biological processes.
Field of Use
The field of use is for the treatment in combination with chemotherapy to treat patients with acute myeloid leukemia (AML) and potentially other hematologic cancers.
IPSCIO Record ID: 183244
License Grant
Licensor granted an exclusive, worldwide license to develop and commercialize cerdulatinib in topical formulation for all indications, excluding oncology to German Licensee.
License Property
Cerdulatinib, is an orally available dual kinase inhibitor that inhibits spleen tyrosine kinase, or Syk, and Janus kinases, or JAK, enzymes that regulate important signaling pathways. Cerdulatinib is being developed for hematologic, or blood, cancers and inflammatory disorders.
Field of Use
Licensee intends to develop it for the topical treatment of a range of dermatologic conditions.
This agreement is for the pharmaceutical industry, excluding oncology use.
IPSCIO Record ID: 283825
License Grant
The Korean Licensor grants to the Licensee of the Cayman Islands an exclusive, sublicensable, transferable license in the Territory to use and otherwise exploit the Licensed Intellectual Properties and any Improvements, not including Improvements to the hyFc Platform technology that is not applicable to the Licensed Product, developed or acquired by Licensor, in connection with the Licensed Product for the Therapeutic Indication.
License Property
Licensed Product means a long-acting efineptakin alpha IL-7 cytokine designated as GX-I7 or Hyleukin covered by valid claims of the Hyleukin Patents.
The patents are for Immunoglobulin fusion proteins; and, Modified Interleukin-7 Protein and Uses Thereof.
TJ107 (HyLeukin®) is the first and only long-acting recombinant human interleukin-7 (rhIL-7) globally to treat chemotherapy induced lymphopenia and cancer.
Field of Use
The therapeutic Indication means treatment of all cancers within the field of Oncology.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
